In an interview with PharmaShots, Bruce C. Cozadd, Chairman and Chief Executive Officer at Jazz Pharmaceuticals shared his views on Vision 2025 to deliver sustainable growth and enhanced value

Shots:

• The company reported Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leader
• The company is expected to generate $5B revenue in 2025, approval of at least 5 additional novel products at the end of the decade, improvement of 5% adjusted operating margin from 2021 to 2025. Additionally, the 2021 revenue is expected to be within the previous range of $3B
• The main objective is to transform the lives of patients and their families, supporting people with serious, complex conditions & helps to provide neuroscience and oncology therapeutic options

Tuba: First let us talk about your experience at the 40th Annual J.P. Morgan Healthcare Conference held on Jan 10, 2022.

Bruce C. Cozadd: During this year’s conference, we had the opportunity to highlight how our company performed in 2021 and outlined our plans for the company’s continued evolution and growth. Most notably, we shared our plans for a bright future and announced Vision 2025.

Jazz demonstrated strong execution throughout 2020 and 2021 as we progressed our transformation to an innovative global biopharmaceutical leader thanks to a culture of bold innovation, collaboration, and inclusion that values integrity, passion, and a relentless pursuit of excellence.

 Tuba: Tell us what we can expect from Vision 2025 and what all does it include?

Bruce C. Cozadd: We’ve set forth Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leader.

Vision 2025 includes the following expectations: 1) generating $5 billion in revenue in 2025; 2) approval of at least five additional novel products by the end of the decade; and 3) realizing a 5% adjusted operating margin¹ improvement from 2021 to 2025, driven by operational excellence.

Tuba: What is the revenue target you are expecting from this vision?

Bruce C. Cozadd: Within Vision 2025, we expect to generate $5 billion in revenue in 2025, with double-digit growth over that time period, including:

• Approximately $2 billion from oxybate franchise, which includes Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution in narcolepsy and idiopathic hypersomnia, Xyrem (sodium oxybate) oral solution, and royalties from Xyrem authorized generics.
• Approximately $2.5 billion from Epidiolex/Epidyolex (cannabidiol) and oncology franchise, including new products Zepzelca (lurbinectedin) and Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn).
• Approximately $0.5 billion from additional growth opportunities, internal clinical development pipeline, and future corporate development.

 Tuba: What are your plans to meet your previously announced 2021 revenue guidance range?

Bruce C. Cozadd: We expect 2021 revenue to meet our previously announced guidance range of $3.02 to $3.1 billion and generate more than $3 billion in annual revenue for the first time. We have a 16-year track record of year over year revenue growth that is poised for continued double-digit, top-line growth. Especially during a tough year of ongoing COVID impacts, this speaks to our ability to execute across our business and is a direct result of our investments in enhanced and expanded capabilities across R&D, commercial excellence, and corporate development.

Tuba: Discuss the new products you are planning to bring in accordance with Vision 2025.

Bruce C. Cozadd: Through Jazz’s Vision 2025, we expect the approval of at least five additional novel products by the end of the decade. The five novel product approvals could come from the compounds we currently have in our pipeline today, as well as from licensing or other future corporate development. We’re actively pursuing corporate development and are pleased to have a robust pipeline. Guided by our patient-centric approach, we’re following the science and unmet patient need to drive forward the development of novel medicines.

 Tuba: Can we have a glance at the therapeutic areas you are looking to introduce for Vision 2025?

Bruce C. Cozadd: Jazz’s existing pipeline has expanded four-fold since 2015 with 18 novel candidates currently in development. With the recent clinical trial initiations, Jazz is entering new disease areas of movement disorders and PTSD, with serious patient unmet needs and substantial market potential. Nabiximols, suvecaltamide (JZP385), and JZP150 are all expected to have near-term data readouts.

While we’re highlighting key programs, we also see a great deal of opportunity across our current pipeline, which includes a number of undisclosed programs in early development, as well as our Cannabinoid Platform.

 Tuba: Tell us about how your Vision 2025 will be beneficial for the patients globally and what rise it will bring for the Pharma industry?

Bruce C. Cozadd: Our purpose is to innovate to transform the lives of patients and their families, and we are focused on supporting people who live with serious, complex conditions, and are committed to bringing forward new life-changing neuroscience and oncology therapeutic options.

Our core strengths enable us to deliver life-changing therapies to patients and value to shareholders. We have successfully grown our company by remaining laser-focused on executing our strategy across commercial, R&D, and corporate development, and delivering important treatments to those living with serious, complex diseases.

 Tuba: Which things motivated you to start Vision 2025?

Bruce C. Cozadd: We announced Vision 2025 to deliver sustainable growth and enhanced value and drive the transformation to an innovative, high-growth, biopharmaceutical leader. Through Vision 2025 and our patient-centric approach, Jazz will continue to bring meaningful treatment options to patients in critical need, be a great place to work for employees, and generate significant value to shareholders. We have a history of successful execution and a proven track record that gives us confidence in our ability to deliver on future performance. 

Vision 2025 focuses on the core components of our business -- commercial, pipeline, and operational excellence -- that enable us to deliver life-changing therapies to patients and long-term value to shareholders.

Source: Canva

About Author:

Bruce C. Cozadd is the Chairman and Chief Executive Officer at Jazz Pharmaceuticals. He brings extensive experience in research and development, manufacturing and sales, and marketing. He received a B.S. from Yale University with a double major in molecular biophysics & biochemistry and economics and an M.B.A. from the Stanford Graduate School of Business.

Related Post: PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer